Date

2025-07-20

Protocol

Protocol changed

Item Changed

Primary outcome(s)

Previous Version

1.Improvement in clinical criteria 1. Improvement of bleeding manifestations 2. Improvement of neurological manifestations (neck muscle power/improvement of ophthalmoplegia/ptosis) 3. Improvement of renal manifestations (urine output) 4. Improvement of local reaction 2.Improvement in laboratory findings and the time taken for improvement of coagulopathy Improvement on hematological abnormalities (Platelets/MAHA in blood picture) Improvement of renal abnormalities (Serum creatinine) Improvement of inflammatory response (white cell count/C-reactive protein)

Next Version

•To assess the safety profile of SL-AVS (number of patients suffering from adverse events) •To evaluate the efficacy of SL-AVS •To assess the optimal dose of SL-AVS for inpatients of HNV bites •To correlate the serum toxin levels pre- and post-AVS administration with clinical findings